BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31974619)

  • 21. Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells.
    Xu W; Wang X; Tu Y; Masaki H; Tanaka S; Onda K; Sugiyama K; Yamada H; Hirano T
    Chem Biol Interact; 2019 Sep; 310():108726. PubMed ID: 31255635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.
    Kodigepalli KM; Li M; Liu SL; Wu L
    Cell Cycle; 2017 Jan; 16(2):179-188. PubMed ID: 27929746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
    Li YY; Wang YF; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ophiopogonin D' induces RIPK1‑dependent necroptosis in androgen‑dependent LNCaP prostate cancer cells.
    Lu Z; Wu C; Zhu M; Song W; Wang H; Wang J; Guo J; Li N; Liu J; Li Y; Xu H
    Int J Oncol; 2020 Feb; 56(2):439-447. PubMed ID: 31894265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in necroptosis during ALDH2‑mediated protection against high glucose‑induced H9c2 cardiac cell injury.
    Fang T; Cao R; Wang W; Ye H; Shen L; Li Z; Hu J; Gao Q
    Mol Med Rep; 2018 Sep; 18(3):2807-2815. PubMed ID: 30015964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
    Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
    Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
    Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis.
    Rohde K; Kleinesudeik L; Roesler S; Löwe O; Heidler J; Schröder K; Wittig I; Dröse S; Fulda S
    Cell Death Differ; 2017 Jan; 24(1):83-97. PubMed ID: 27834956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
    Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
    Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
    Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
    Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin.
    Shrestha A; Mehdizadeh Gohari I; McClane BA
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848291
    [No Abstract]   [Full Text] [Related]  

  • 40. Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML.
    Wang JD; Xu JQ; Long ZJ; Weng JY
    Clin Transl Oncol; 2023 Jun; 25(6):1805-1820. PubMed ID: 36899123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.